3:26 PM
 | 
Dec 07, 2017
 |  BC Extra  |  Clinical News

Sage jumps on Phase II data for MDD candidate

Sage Therapeutics Inc. (NASDAQ:SAGE) gained $64.37 (70%) to $156.27 on Thursday after reporting that SAGE-217 met the primary endpoint in a Phase II trial to treat moderate to severe major depressive disorder. Sage added over $2 billion to its market cap on the news.

On the 89-patient trial's primary endpoint, once-daily 30 mg oral SAGE-217 for 14 days significantly reduced mean Hamilton Rating Scale for Depression (HAM-D)...

Read the full 313 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >